4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting
- 1 November 2003
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 146 (5) , 855-861
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- The 4G/5G promotor polymorphism of the plasminogen activator inhibitor‐1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patientsClinical Cardiology, 2001
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Allelic discrimination using fluorogenic probes and the 5′ nuclease assayGenetic Analysis: Biomolecular Engineering, 1999
- Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma ConcentrationsArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Inhibitory Role of Plasminogen Activator Inhibitor-1 in Arterial Wound Healing and Neointima FormationCirculation, 1997
- Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen ActivationExperimental Cell Research, 1997
- Plasminogen Activator Inhibitor-1 Promoter 4G/5G Genotype and Plasma Levels in Relation to a History of Myocardial Infarction in Patients Characterized by Coronary AngiographyArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosisAmerican Heart Journal, 1996
- Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure.Circulation, 1994